Mainz Biomed N.V. has announced an agreement with Quest Diagnostics to support the commercialization of its NextGen screening test for colorectal cancer. The agreement involves Quest providing clinical trial laboratory services for Mainz Biomed’s ReconAAsense study, with the aim of developing data supporting FDA validation of the NextGen test.